SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Ignelzi Troy A.	2. Date of Event Requiring States (Month/Day/Yea 06/25/2013	ment	3. Issuer Name and Ticker or Trading Symbol <u>Esperion Therapeutics, Inc.</u> [ESPR]					
(Last) (First) (Middle) C/O ESPERION THERAPEUTICS, INC.			4. Relationship of Reporting Perso (Check all applicable) Director	10% Owne	r (M	5. If Amendment, Date of Original Filed (Month/Day/Year)		
46701 COMMERCE CENTER DRIVE			X Officer (give title below)	Other (spe below)	· 0.	6. Individual or Joint/Group Filing (Check Applicable Line)		
(Street) PLYMOUTH MI 48170			Vice Preside	nt			y One Reporting Person y More than One erson	
(City) (State) (Zip)								
Table I - Non-Derivative Securities Beneficially Owned								
1. Title of Security (Instr. 4)			Amount of Securities Beneficially Owned (Instr. 4)			4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)								
1. Title of Derivative Security (Instr. 4)	2. Date Exerce Expiration Day/ (Month/Day/	ate	3. Title and Amount of Securi Underlying Derivative Securit		4. Conversion or Exercise	Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)		
Stock Option (right to buy)	(1)	04/02/2020	Common Stock	21,471	1.26	D		
Stock Option (right to buy)	(2)	05/19/2021	Common Stock	2,147	1.54	D		
Stock Option (right to buy)	(3)	01/16/2023	Common Stock	17,177	2.1	D		

Explanation of Responses:

1. Fully vested.

2. The option vests in equal quarterly installments over a four-year period beginning from February 17, 2011.

3. The option vests in equal quarterly installments over a four-year period beginning from January 16, 2013.

/s/ Richard B. Bartram, by power of attorney

06/25/2013

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

on Date

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby authorizes each of Tim M. Mayleben, Richard B. Bartram, and Troy A. Ignelzi, of Esperion Therapeutics, Inc., a Delaware corporation (the "Company"), individually to execute for and on behalf of the undersigned, in the undersigned's capacity as an Officer and/or Director of the Company, Forms 3, 4 and 5, and any amendments thereto, and cause such form(s) to be filed with the United States Securities and Exchange Commission pursuant to Section 16(a) of the Securities Act of 1934, relating to the undersigned's beneficial ownership of securities in the Company. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all such attorneys-in-fact, or such attorneys-in-facts' substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacities at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the earliest of: (1) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company; (2) this Power of Attorney is revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact; or (3) as to a specific attorney-in-fact, the employment of such attorney-in-fact with the Company is terminated.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 20th day of June, 2013.

/s/ Troy A. Ignelzi
 (Sign Name)
Troy A. Ignelzi
 (Type Name)